Company intelligence
neotis
Immunotherapies for fibrotic disease
Biotechnology Research
5 employees
Founded 2025
1 public signals
About neotis
Neotis is developing T-cell engagers to deplete aberrant epithelial cells driving pulmonary fibrosis. The senescent antigen targets from our proprietary NTS platform have 10x greater specificity than our competitor's approaches. Our lead indication is idiopathic pulmonary fibrosis, a fatal disease with no cure. We're building a new class of therapeutics for age-related disease.
Verified activity
Signals from neotis
1 published signal